Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer-2

Ubated with survivin-2B peptide (B), many spots were visualized. These findings demonstrate that CD8-positive T cells separated from the patients' PBMCs had a peptide-specific IFN-γ response.<p><b>Copyright information:</b></p><p>Taken from "Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer"</p><p>http://www.translational-medicine.com/content/6/1/24</p><p>Journal of Translational Medicine 2008;6():24-24.</p><p>Published online 10 May 2008</p><p>PMCID:PMC2430193.</p><p></p

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer-0

In size of the metastatic lesions. Tumor marker levels did not increase rapidly.<p><b>Copyright information:</b></p><p>Taken from "Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer"</p><p>http://www.translational-medicine.com/content/6/1/24</p><p>Journal of Translational Medicine 2008;6():24-24.</p><p>Published online 10 May 2008</p><p>PMCID:PMC2430193.</p><p></p

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer-1

Imulated , were stained with the tetramers at 37°C for 20 min, followed by staining with FITC- or PerCP-conjugated anti-CD8 mAb (Beckton Dickinson Biosciences) at 4°C for 30 min. Cells were washed twice with PBS before fixation in 1% formaldehyde. Flow cytometric analysis was performed using FACSCalibur and CellQuest software (BD Biosciences). The frequency of CTL precursors was calculated as the number of tetramer-positive cells divided by the number of CD8-positive cells. The peptide-specific CTL frequency is indicated as the percentage of tetramer-positive CTL cells among CD8-positive T cells before the first vaccination and after the fourth vaccination. The peptide-specific CTL frequency after the fourth vaccination (B) was compared with that before the first vaccination (A). In the second protocol with the peptide mixed with IFA, the peptide-specific CTL frequency was increased in all 4 patients (100%).<p><b>Copyright information:</b></p><p>Taken from "Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer"</p><p>http://www.translational-medicine.com/content/6/1/24</p><p>Journal of Translational Medicine 2008;6():24-24.</p><p>Published online 10 May 2008</p><p>PMCID:PMC2430193.</p><p></p